抗真菌药
氟胞嘧啶
白色念珠菌
白霉素类
抗真菌
微生物学
两性霉素B
抗真菌药
药品
蛋白酶
生物
杀菌剂
抗药性
氟康唑
卡斯波芬金
药理学
生物化学
酶
植物
作者
Goldman Rc,Frost Dj,Capobianco Jo,Sunil Kadam,Rasmussen Rr,Celerino Abad‐Zapatero
出处
期刊:PubMed
日期:1995-12-01
卷期号:4 (4): 228-47
被引量:13
摘要
The incidence of severe, life-threatening fungal infections has increased dramatically over the last decade. Unfortunately, in practice the arsenal of antifungal drugs is limited to flucytosine, a few approved azoles, and polyenes, mainly amphotericin B. This situation is rather precarious in view of the extended spectrum of fungi causing severe disease in immunocompromised patients, development of resistance to some of the currently used agents, and the minimal fungicidal activity of the azoles. Although lagging behind the need for new antifungal agents, the study of fungal biochemistry, physiology, and genetics has undergone a resurgence to new heights of activity, thus providing a framework on which to build drug discovery programs in several new areas, two of which will be discussed in detail: the biology of Candida albicans secreted aspartyl protease with respect to inhibitor discovery, evaluation, and possible clinical utility; and the fungal cell wall beta-glucans with respect to the mechanism and regulation of synthesis and target sites for drug inhibition.
科研通智能强力驱动
Strongly Powered by AbleSci AI